Informed Consent in Aesthetics Is Incomplete Without Psychological Risk Disclosure.

Informed consent in aesthetics has a clear shape when it comes to physical risks. Before any procedure, patients are told about infection, bruising, scarring, asymmetry, vascular occlusion, and allergic reaction. These risks are disclosed as standard, to every patient, regardless of whether the practitioner suspects that individual is likely to experience them. Nobody asks whether a patient looks like they might scar badly before deciding whether to mention scar risk. Nobody waits for signs of infection susceptibility before disclosing that infections can occur. The risks are known, they are material to the patient's decision, and they are disclosed; that is what informed consent requires.

Why Psychological Risks Are Crucially Important to Informed Consent in Aesthetics

Cosmetic procedures are chosen for psychological, not medical, reasons. A patient seeking rhinoplasty is not seeking a differently shaped nose for its own sake. They are seeking relief from distress about their appearance, an improvement in confidence, an alignment with identity, a change in how they feel in social situations, or some version of a better life than the one they currently have. Those are the outcomes the procedure is expected to deliver, and they are psychological outcomes. When a procedure fails to deliver them — when the patient is left with a technically acceptable result and the same distress they walked in with — that is a harm. Not the same kind of harm as a surgical complication, but it is a harm that was foreseeable, documented, and directly relevant to the decision to proceed.

Where the motivation is subjective, the risk disclosure has to include subjective outcomes. If a procedure is chosen for psychological reasons, psychological outcomes belong in the consent conversation. Not because the practitioner suspects vulnerability. Not because the patient has disclosed a psychiatric history. But because any reasonable person considering that procedure would want to know that cosmetic treatment cannot resolve a distorted relationship with appearance, that dissatisfaction after a technically successful procedure is a documented pattern, and that for a substantial proportion of cosmetic patients, the psychological outcome they were seeking is not guaranteed, even when the procedure is technically successful.

Now consider Body Dysmorphic Disorder, or BDD, a mental health condition characterised by an intense and distressing preoccupation with a perceived flaw in appearance. Meta-analyses of cosmetic surgery patients place its prevalence at between 19% and 24% — roughly one in five people seeking cosmetic procedures. (PubMed, MDPI) For context, the estimated rate of allergic reactions or eyelid/brow drooping (ptosis) to commonly used cosmetic injectables like Botulinum toxin sits well below 5% (PubMed); yet those risks are disclosed as standard. BDD, which is strongly associated with poor psychological outcomes after cosmetic treatments, is not even mentioned in standard consent conversations. That is a fundamental inconsistency in how informed consent is applied, and it has no principled justification.

The outcomes data for BDD in cosmetic settings are not ambiguous. Studies consistently show that the majority (96%) of BDD patients who undergo cosmetic procedures experience no improvement in their symptoms, and a significant proportion experience worsening. (PubMed) The disorder does not resolve because a feature has been altered. It is a disorder of perception, not of appearance, and surgery cannot reach it. Rates of depression, suicidal ideation, and completed suicide in people with untreated or under-treated BDD are substantially elevated above the general population. (NCBI) A cosmetic procedure that fails to deliver the relief the patient was seeking can precipitate or accelerate those outcomes. 

It is worth acknowledging a genuine complexity here: BDD is characterised in many cases by poor or absent insight — some patients hold beliefs about their appearance with delusional conviction, and for those patients, risk information may not land in the way it would for someone with full insight into their condition. That is a real clinical reality. It is also, however, an argument for disclosure rather than against it. A patient who has never heard of BDD, does not know they may be affected by it, and has never been told that cosmetic treatment is unlikely to resolve the kind of distress they are experiencing is in the worst possible position after a procedure that fails to help them. Disclosure does not guarantee a different decision in the first instance; but it plants information that may become the most important thing a patient recalls when that procedure leaves them no better off — and may be what redirects them toward support that can actually help, rather than toward another procedure that cannot.

Why Does the Aesthetic Industry Keep Failing Patients? 

Instead of doing the sensible thing and mandating the disclosure of psychological risks, industry guidance is pushing practitioners to detect vulnerable patients first and disclose selectively, or refer them to a specialist. Leaving aside whether identifying these patients is practically achievable — and research consistently shows it is not (PMC) — it fundamentally misunderstands how informed consent works. Disclosure is not conditional on detection. It has never been, for any other category of risk.

We do not ask practitioners to identify which patients are likely to develop an infection before explaining infection risk. We do not ask them to assess scarring susceptibility before disclosing the possibility of scarring. We do not ask them to predict allergic reactions before disclosing that allergic reactions may occur. The obligation to disclose does not depend on the practitioner's suspicion about the individual patient. It depends on whether a patient would consider the risk material to their decision. 

Current guidance in aesthetic medicine acknowledges psychological factors as part of the consent conversation, but does not treat them as a disclosure standard. The General Medical Council (GMC) asks doctors to consider psychological vulnerabilities. The Royal College of Surgeons (RCS) lists BDD as something practitioners should be alert to. The Joint Council of Cosmetic Practitioners (JCCP) links consent to psychological preparedness. All of this frames psychological risk as something the practitioner should assess, rather than something every patient should be told about. The distinction matters enormously. Assessment puts the practitioner in control of what the patient is allowed to know, because psychological risk is only discussed if the practitioner decides the patient looks vulnerable enough to trigger that conversation. Disclosure does the opposite. It gives every patient the information they need before they decide. Patients do not benefit from being silently assessed for risks they were never told existed. They benefit from clear, relevant information that lets them give consent with their autonomy intact. The result of treating psychological risk as a matter of practitioner assessment rather than patient disclosure and autonomy is a standard that would never be accepted for physical risks of equivalent or lesser prevalence. There is no coherent reason to accept it here.

Cosmetic procedures are different from most clinical interventions because they change the body in pursuit of something deeply subjective: how a person sees themselves, how they hope to feel, and what they believe the change will mean. The outcome is physical, but the meaning of that outcome is psychological. A consent process that explains the physical risks while ignoring the psychological ones does not give the patient the full picture. It is partial disclosure presented as informed consent, and patients deserve better.

---

Disclosure statement

This article is published by PREPÆRE, a pre-consultation education platform built for the cosmetic sector. PREPÆRE gives patients structured information about motivations, expectations, procedure limitations, and psychological risks before they meet a practitioner — and creates a documented record that this has taken place.

The argument in this article reflects PREPÆRE's core premise: psychological risks are material to the decision to undergo cosmetic treatment and should be disclosed clearly and consistently to every patient, not only when a practitioner suspects a problem. That is not a burden on practitioners. It is a disclosure standard the industry does not yet have, and one that patients have always deserved.

If you work in cosmetic practice, medical malpractice insurance, claims, underwriting, risk management, or medico-legal defence, and you are considering how psychological risk disclosure could be built into cosmetic informed consent more consistently, we would welcome the conversation. To discuss PREPÆRE, get in touch here: info@prepaere.com.